Cluster Headache

<section class="Section" data-sectioncode="34089-3"><a name="s30"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Galcanezumab-gnlm is a humanized IgG4 monoclonal antibody specific for calcitonin-gene related peptide (CGRP) ligand. Galcanezumab-gnlm is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Galcanezumab-gnlm is composed of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains and has an overall molecular weight of approximately 147 kDa.</p><p>EMGALITY (galcanezumab-gnlm) injection is a sterile, preservative-free, clear to opalescent and colorless to slightly yellow to slightly brown solution, for subcutaneous use. EMGALITY is supplied in a 1 mL single-dose prefilled pen to deliver 120 mg of galcanezumab-gnlm or a 1 mL single-dose prefilled syringe to deliver 100 mg or 120 mg of galcanezumab-gnlm. Each mL of solution contains  100 mg or 120 mg of galcanezumab-gnlm; L-histidine (0.5 mg); L-histidine hydrochloride monohydrate (1.5 mg); Polysorbate 80 (0.5 mg); Sodium Chloride (8.8 mg); Water for Injection, USP. The pH range is 5.3 - 6.3.</p></section>

EMGALITY

galcanezumab

galcanezumab-gnlm

1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector

Emgality

1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector [Emgality]

1 ML galcanezumab-gnlm 120 MG/ML Prefilled Syringe

1 ML galcanezumab-gnlm 120 MG/ML Prefilled Syringe [Emgality]

1 ML galcanezumab-gnlm 100 MG/ML Prefilled Syringe

1 ML galcanezumab-gnlm 100 MG/ML Prefilled Syringe [Emgality]

<section class="Section" data-sectioncode="34089-3"><a name="LINK_2c8e4016-3376-4164-bb3b-b7547946b92d"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Fremanezumab-vfrm is a fully humanized IgG2Δa/kappa monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Fremanezumab-vfrm is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. The antibody consists of 1324 amino acids and has a molecular weight of approximately 148 kDa.</p><p>AJOVY (fremanezumab-vfrm) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for subcutaneous injection, supplied in a single-dose 225 mg/1.5 mL prefilled autoinjector and a single-dose 225 mg/1.5 mL prefilled syringe. </p><p>Each prefilled autoinjector or prefilled syringe delivers 1.5 mL of solution containing 225 mg fremanezumab-vfrm, disodium ethylenediaminetetraacetic acid dihydrate (EDTA) (0.204 mg), L-histidine (0.815 mg), L-histidine hydrochloride monohydrate (3.93 mg), polysorbate-80 (0.3 mg), sucrose (99 mg), and Water for Injection, and has a pH of 5.5.</p></section>

AJOVY

fremanezumab-vfrm

fremanezumab

1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe

Ajovy

1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy]

1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector

1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector [Ajovy]

Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be used to treat cluster headaches during a cluster headache period. The most frequently reported side effect is injection site reactions. Additionally, there are no known drug interactions with Emgality.

Emgality is FDA approved for the following indications: Migraine and Cluster Headaches. 


Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals: Migraine 

Letter of Medical Necessity: Migraine 

Coverage Authorization Appeals: Episodic Cluster Headache 

Letter of Medical Necessity: Episodic Cluster Headache 

Enroll in Savings Program

Lilly Cares Patient Assistance Program Eligibility Check 

How To Rx in EMR 

Other HCP Resources 

About Emgality: Migraine 

Taking Emgality: Migraine 

Patient Stories: Migraine 

Migraine Patient Questionnaire

About Emgality: Episodic Cluster Headache 

Taking Emgality: Episodic Cluster Headache 

Instructions For Use (Video): Migraine 

Instructions For Use (Video) : Episodic Cluster Headache 

Instructions For Use (120mg Pen): Migraine 

Instructions For Use (120mg Syringe): Migraine 

Instructions For Use (100 mg Syringe): Episodic Cluster Headache

Enroll Patient in Savings Card Program - HCP

Lilly Cares - Online Application

Lilly Cares Application - English

Lilly Cares Application - Spanish

Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side effect is injection site reactions. Ajovy does not seem to cause constipation. Additionally, there are no known drug interactions.

Ajovy is FDA approved for the following indications: Migraine prevention. 


Report Adverse Event 

Formulary Information

Coverage Authorization Appeals

Letter of Medical Necessity 

Enroll in Patient Savings Program 

Teva Patient Assistance Program 

About Ajovy 

Side Effects 

Taking Ajovy 

Patient Stories 

Patient Resources: Patients Considering Ajovy 

Patient Resources: Patients On Ajovy 

Instructions For Use (Prefilled Syringe) : Migraine Prevention 

Instructions For Use (Prefilled Autoinjector): Migraine Prevention 

Sharps Container

Doctor Discussion Guide: Patients Considering Ajovy

Migraine Tracker 

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Migraine Prevention

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

®()	®()

Prescription Only	Prescription Only
Dosage & Administration
Administration
Learn more.	Learn more.
Dosing
Learn more.	Learn more.
Latin Shorthand
Learn more.	Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Learn more.	Learn more.
Annual Cap
Learn more.	Learn more.
Assistance Expiration
Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Physician Advisory
Adverse Reactions
Learn more.	Learn more.
Mechanism of Actions (MoA)
Learn more.	Learn more.
Special Populations

® Alternatives